Administration of fibroblast interferon to patients with advanced breast cancer: possible effects on skin metastasis and on hormone receptors

Eur J Cancer Clin Oncol. 1982 Oct;18(10):929-35. doi: 10.1016/0277-5379(82)90240-1.

Abstract

Eleven patients with metastasized breast cancer received 8 intramuscular injections of 6 x 10(6) units of human fibroblast interferon over a period of 40 days. The injections did not cause local irritation or inflammation. Fever occurred in only 1 of the 11 patients. Although several types of metastases were monitored, only skin nodules consistently (10 out of 11 patients) exhibited changes that were suggestive of a therapeutic effect of the treatment regimen: either a simple decrease in size of some nodules or central necrosis accompanied by an inflammatory reaction. NK-activity of peripheral blood leukocytes was significantly increased after administration of the first dose; the effect of subsequent injections was less clear. Receptors for estrogens and progestogens were increased in the tumor biopsies of 2 out of 2 and 5 out of 6 patients tested respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / immunology
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / therapy*
  • Female
  • Humans
  • Injections, Intramuscular
  • Interferon Type I / administration & dosage
  • Interferon Type I / adverse effects
  • Interferon Type I / therapeutic use*
  • Killer Cells, Natural / immunology
  • Lung Neoplasms / secondary
  • Lung Neoplasms / therapy
  • Receptors, Estrogen / metabolism
  • Receptors, Progesterone / metabolism
  • Skin Neoplasms / secondary*
  • Skin Neoplasms / therapy

Substances

  • Interferon Type I
  • Receptors, Estrogen
  • Receptors, Progesterone